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ABSTRACT
We assessed the safety and efficacy of Formulated Collagen Gel (FCG) alone and
with Ad5PDGF-B (GAM501) compared with Standard of Care (SOC) in patients
with 1.5–10.0 cm2 chronic diabetic neuropathic foot ulcers that healed< 30% dur-
ing Run-in. Wound size was assessed by planimetry of acetate tracings and photo-
graphs in 124 patients. Comparison of data sets revealed that acetate tracings
frequently overestimated areas at some sites. For per-protocol analysis, 113 patients
qualified using acetate tracings but only 82 qualified using photographs. Prior an-
imal studies suggested that collagen alone would have little effect on healing and
would serve as a negative control. Surprisingly trends for increased incidence of
complete closure were observed for both GAM501 (41%) and FCG (45%) vs. Stan-
dard of Care (31%). By photographic data, Standard of Care had no significant
effect on change in wound radius (mm/week) from during Run-in to Week 1
(0.06 0.32 to 0.78 1.53, p5ns) but both FCG (0.08 0.61 to 1.97 1.77,
p < 0.002) and GAM501 (0.02 0.58 to 1.46 1.37, p < 0.002) significantly in-
creased healing rates that gradually declined over subsequent weeks. Both GAM501
and FCGappeared to be safe andwell tolerated, and alternate dosing schedules hold
promise to improve overall complete wound closure in adequately powered trials.
Approximately 24 million people in the US have diabetes
and 800,000 new cases are identified each year.1 Many
diabetic patients develop diabetic peripheral neuropathy.
Among all diabetic patients 15% will eventually develop a
Diabetic neuropathic Foot Ulcer (DFU), 25% of whom
will have a foot amputation and subsequent 3-year sur-
vival rate of 50% despite currently available therapies.2,3
The current Standard of Care (SOC) for DFU includes
surgical debridement, moist dressing changes, and
off-loading.4 SOC treatment results in healing incidences
of approximately 25% after 12 weeks and 30% after
20 weeks.5 In chronic DFU, the healing process is im-
paired in part due to deficiency of growth factors.6–9 Cur-
rently available secondary interventions include living skin
equivalents (e.g., Apligraf, Organogenesis Inc., Canton,
MA; Dermagraft, Advanced Biohealing Inc., Westport,
CT), Becaplermin (Regranex, platelet-derived growth fac-
tor-B homodimer [PDGF-BB], Systagenix Wound Man-
agement, Gargrave, UK), hyperbaric oxygen, negative
pressure devices, antibiotics for infection, and specialized
dressings. These interventions provide moderate improve-
ment over SOC, generally only 15–20%, and may be ex-
pensive and time consuming. For example Becaplermin is
Ad5 Adenovirus serotype 5 vector
Ad5PDGF-B E1-deleted adenovirus serotype 5 encoding human
platelet-derived growth factor-B
CFU Colony forming unit
DFU Diabetic foot ulcer
DSMB Data and safety monitoring board
FCG Formulated Collagen Gel
GAM501 Gene Activated Matrix 501, a proprietary product
ITT Intention to treat
PDGF-B Platelet derived growth factor B gene
PDGF-BB Platelet derived growth factor BB
PP Per-protocol
SAP Statistical analysis plan
SOC Standard of Care
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designed to be applied daily for up to 20 weeks due to short
persistence of the growth factor protein in the wound.6
While exogenously applied growth factors can improve
healing, a more convenient and less burdensome applica-
tion method would be helpful, particularly since proper
wound care and compliance are frequently problematic in
diabetic patients. Delivery of a growth factor gene and
transient protein expression at the site where it is
needed could overcome the need for daily protein admin-
istration. In view of the continuing need for better
therapeutics, particularly in the case of hard to treat
wounds, Tissue Repair Company (a subsidiary of Card-
ium Therapeutics Inc., San Diego, CA) developed a
Formulated Collagen Gel (FCG) and a replication-incom-
petent adenovirus serotype 5 (Ad5) vector. In preclinical
wound healing models the PDGF-B gene inserted into the
adenovector mixed with FCG was the most effective on
indices of wound healing among a number of growth fac-
tor genes evaluated10,11 while FCG alone had little effect.
FCG contains 2.6% bovine collagen in a specialized buffer
providing protein stabilization and promotion of a bal-
anced healing environment. FCG is believed to have sev-
eral important attributes: it holds the Ad5 vector within
the ulcer site by electrostatic attraction (positively charged
collagen, negatively charged adenovector), it has binding
sites for growth factors (i.e., PDGF-BB, 160 amino acid
form), and it provides a scaffold for migration of cells re-
sponsible for generation of granulation tissue.12 In several
preclinical models, application of FCG containing Ad5-
PDGF-B (GAM501) resulted in transfection of wound re-
pair cells, provided sustained PDGF-BB production, and
caused enhanced migration and proliferation of inflamma-
tory cells, endothelial cells, fibroblasts, and other connec-
tive tissue cell types.10,11 This report describes the results of
a Phase 2 blinded, controlled 12 week trial of three inter-
ventions (GAM501, FCG, and SOC) in diabetic patients
with chronic, non-healing neuropathic ulcers.
MATERIALS ANDMETHODS
The primary objective of the trial was to evaluate the
safety and efficacy of GAM501 vs. FCG and SOC on the
incidence of complete ulcer closure. The study was initially
planned to enroll up to 210 patients and designed for a
projected alpha of 0.05 and a beta (power) of 90% based
on the phase 1/2 trial of GAM501 and historical SOC
closure incidences of about 25–30%.5,13 Enrollment crite-
ria included type 1 or 2 diabetic patients over age 18 with a
Wagner Classification Grade 1 cutaneous lower extremity
ulcer between 1.5 and 10.0 cm2 in area that had been
present for at least 6 weeks. Patients had peripheral
neuropathy (inability to perceive 10 g pressure using a
Semmes-Weinstein 5.07 monofilament (North Coast Med-
ical, Gilroy, CA) in the peri-ulcer area) and adequate
blood flow (TcpO2 > 40mmHg or a toe pressure
40mmHg). Exclusion criteria included HbA1c > 12%,
ulcers on the heel, cellulitis, biopsy positive for beta hemo-
lytic streptococci or total bacterial load >1106CFU/g
tissue (treatment with local antibiotics once and re-biopsy
was allowed), or a decrease in ulcer size of >30% from
screening to Treatment Day 1 indicating an ulcer likely to
heal with SOC.5 For complete criteria see http://clinical-
trials.gov/ct2/show/NCT00493051.
Twenty-two sites with institutional review board ap-
proval of the protocol, in compliance with the Declaration
of Helsinki (as amended, Oct 2000), randomized patients.
Following qualification and informed consent, patients
underwent surgical debridement of the ulcer, biopsy for
culture, clinical ulcer assessment, ulcer photograph, and
ulcer size measurement (acetate tracing for planimetry) on
Day 14 to start a screening 2-week Run-in period with
SOC treatment. The primary data was the site-generated
weekly acetate tracing of the wound edge faxed to a central
laboratory for area measurement (Canfield, Fairfield, NJ);
weekly ulcer photographs were archived at the same cen-
tral laboratory as a back up if confirmation was needed.
All patients wore a special off-loading orthopedic shoe
(DHWalker; Ossur, Coconut Creek, FL) during the Run-
in period and throughout the trial. On Day 3 repeat clin-
ical ulcer assessment was performed and qualified patients
were randomized into one of five treatment groups: (1)
SOC, (2) FCG one application on Day 1, (3) FCG two
applications on Days 1 and 29 (4 weeks), (4) GAM501 one
application on Day 1, (5) GAM501 two applications on
Days 1 and 29 (4 weeks). Randomization ratios were:
1 : 1 : 1 : 2 : 2.
The Day 1 visit consisted of surgical debridement of the
ulcer if medically necessary, clinical assessment of the ulcer
site, ulcer photograph, and ulcer size measurement by
acetate tracing to confirm that the patient qualified. Study
treatment was administered to the wound in the GAM501
and FCG groups by study personnel unblinded only to
treatment vs. SOC (blinded to GAM501 vs. FCG), and the
wound was covered and left undisturbed for one week.
Principal Investigators remained completely blinded. Pa-
tients randomized to the SOC group continued with daily
dressing changes. All patients were seen and assessed
weekly until ulcer closure or week 12. Patients whose ulcer
closed (complete epithelialization with no drainage)
entered a 12 week follow-up phase to assess durability;
non-healing patients exited the study at week 12. An in-
dependent Data and Safety Monitoring Board (DSMB)
reviewed the data periodically.
When the trial had enrolled over half of the planned
number of patients, the DSMB reported that there were no
safety concerns but that enrollment was slower than pro-
jected. While completely blinded to treatment assignment,
the company reviewed the slow patient recruitment rate,
its long-term development plan, and blinded investigator
reports of very rapid initial healing rates in some patients.
Initial rapid healing rates in response to treatment with
GAM501 had also been noted in the Phase 1/2 trial.13
Taking these factors into consideration, a decision was
made to modify the trial design to examine initial healing
rates as an additional primary end point, to combine the
one- and two-dose treatment arms and reduce the
combined study group sizes (and thus overall patient
enrollment). Following this determination and before un-
blinding the trial, the Statistical Analysis Plan (SAP1) was
written to combine the one- and two-dose treatment arms
of both GAM501 and FCG, making the trial exploratory,
since the initial healing rate would not be affected by the
second treatment and the power to detect a treatment
effect on initial healing rate would thus be increased. The
SAP1 also specified that the rate of change of wound ra-
dius (wound-healing rate) over the first 4 weeks and the
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incidence of complete wound closure in the combined one
and two dose groups were co-primary endpoints, and that
the analysis would be per-protocol. The weekly healing
rates were secondary endpoints. Early wound healing rates
have been shown to predict eventual wound closure and
are a variable that likely would be affected by an effective
treatment compared with SOC.14 Note that the primary
interest of the trial was to compare GAM501 to SOC and
FCG as it had been assumed based on a number of prior
animal studies that FCG alone would not have an effect
and be a negative control.
As enrolled, 124 treated patients constituted the inten-
tion to treat (ITT) population included in the demographic
and safety analyses. After database lock a blinded data
review identified 11 patients with important protocol devi-
ations who were not included in the Per-Protocol analysis
(PP). Since the trial was exploratory the statistical analyses
were perfomed PP on the resulting 113 patients.
During initial analyses, some major visual discrepancies
in size and shape of the wound between acetate tracings
and the corresponding photographs were noted. Details
reported in the Results section justified an analysis using
the photographs as the primary data source and a second
exploratory Statistical Analysis Plan (SAP2) was finalized.
The wound photographs had rulers included for calibra-
tion, and were taken from the same distance by means of a
fixed focal length camera. Five blinded observers experi-
enced or trained in wound evaluation independently
traced all photographs from Day 14 through Week 8
using NIH Image J software. Using the coefficient of vari-
ation (SD/Mean) > 0.1 as a guide, predefined rules for
averaging the data from the five observers or repeating the
measurements were included in SAP2. Areas for a few
problematic photographs were determined by group con-
sensus. Determination of complete wound closure by the
sites was not changed.
Data analysis
All data were entered into a web-based case report form.
Wound radius used to track wound-healing rate was cal-
culated as: R5SQRT(Area/p) and change in radius was
expressed as mm/week. The total Run-in period varied
widely so the healing rate during Run-in was calculated
using the actual number of days/seven. Missing data were
not imputed. Cumulative healing rates over multiple weeks
(i.e. Day 1–Week 2, Day 1–Week 3, etc) were calculated
from linear least squares fit for radius vs. time. Weekly
healing rate was calculated as the difference in radius
between sequential measurements. Change in radius over
time more closely approximates tissue growth rates than
area change.15
RESULTS
A total of 129 patients were randomized; 124 patients
qualified and were treated on Day 1 and constitute the ITT
population. Demographic data, ulcer size and duration for
the ITT population were similar between groups (Table 1).
The predominant ulcer location was plantar in 89% of
SOC, 88% of FCG, and 78% of GAM501 patients.
Review of the data by the DSMB found GAM501 and
FCG to be safe in the ITT population; no adverse events
were classified by the Investigators as likely or definitely
related to treatment.
Of the 124 patients treated, 116 completed the study and
eight were withdrawn (Table 1). For SAP1 the blinded
data review identified 11 patients with protocol deviations
for inclusion/exclusion criteria not met and treatment or
visit non-compliance leaving 113 patients in the PP popu-
lation. A 10% variation was allowed so that minimum
wound size for inclusion was 1.35 cm2 and maximum
allowable decrease from Day 14 to Day 1 was 33%.
Ulcer closure incidences were 5/16 (31%) in SOC, 14/31
(45%) in FCG, and 27/66 (41%) in GAM501, a non-sig-
nificant trend. Using acetate data, there were no significant
differences in wound radius healing rates from Day 1 to
Week 4 between groups (data not shown). The finding that
GAM501 and FCG had nearly identical effects was sur-
prising as several non-diabetic and diabetic preclinical
models had found GAM501 to be superior.10,11,16 To
investigate this observation the wound photographs and
acetate tracings were printed for visual comparison; the
striking differences noted between the acetate tracing and
corresponding photograph onDay 1 from some sites led to
blinded wound photograph analysis as primary data using
SAP2.
The results from the blinded photographic data review
were unexpected. Wound area by photograph on Day 1
was less than 1.35 cm2 in 33 out of 133 patients (29%) and
10 patients had wound size decreases of greater than 33%
during Run-in; eight patients met both exclusion criteria,
making a total of 35 patients (31%) that likely should have
been excluded from enrollment on Day 1. An additional
patient was excluded because the wound covered a curved
surface and area by photograph could not be accurately
determined. Five patients excluded from SAP1 were found
to qualify for SAP2, leaving a total of 82 patients for anal-
ysis in SAP2.
The mean wound size determined by acetate and pho-
tograph for the SAP2-excluded and—included patients
through Week 2 is shown in Table 2. On Day 1 the differ-
ence between acetate and photographic areas was 163%
for excluded patients and 20% for included patients
(p < 0.001). The data revealed systematically greater area
measurements with acetate tracings compared with photo-
graphs with differences that were very large on Day 1 and
much less thereafter. Exclusions were clustered among a
few sites: six sites had 26 of 43 (60%) patients excluded in
SAP2; the remaining 14 sites had 8 of 74 patients (11%)
excluded in SAP2.
The 12-week complete closure incidences in SAP2 were:
SOC: 4/13 (31%), FCG: 6/17 (35%), and GAM501: 21/51
(41%), p5ns. Note that the complete closure incidence for
patients excluded using photographs as primary data in
SAP2 was 17 of 35 (49%) suggesting that these small and/
or rapidly closing wounds were likely to close without
intervention as reported in published literature.5
Table 3 (SAP2) shows the cumulative wound healing
rates for Run-in and for Day 1 through Week 4. Pair-wise
comparisons between the three groups by ANOVA found
that the only significant difference was between FCG and
SOC for Day1–Week1 and Day1–Week2. Within each
group all subsequent healing rates were compared with
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Run-in by paired t-tests. In the SOC group there was no
significant change in healing rate from Run-in until Day1–
Week2. In the FCG and GAM501 groups, all cumulative
healing rates were significantly different than Run-in.
We reasoned that the application of a wound healing
adjuvant should increase the healing rate promptly after
application and have a time-limited effect. Therefore, we
tested whether the weekly healing rate was different for the
4 weeks after treatment than during Run-in for each
group. Results in Table 4 from SAP2 show that Run-in
healing rates for all groups were essentially zero. The
weekly healing rates for SOC were never statistically
different than zero. The GAM501 weekly rate was signifi-
cantly non-zero through Week 4 and the FCG rate was
significantly non-zero through Week 2. Table 4 also shows
the statistical results for change in healing rate from Run-
in. In the SOC group only the Week 2–Week 3 rate
was increased over baseline. In the FCG group, the first
2 weeks were significantly increased from baseline. In the
GAM501 groups, all subsequent healing rates were signifi-
cantly increased over Run-in.
DISCUSSION
The demographics of our patient population are similar to
what has been reported in previous studies of neuropathic
Wagner Class 1 DFUs, and there were no differences be-
tween groups. Entry criteria excluded patients with small
wounds or with wounds decreasing in area more than 30%
in a 2 week screening period; such wounds are unreliable
Table 2. Photographic and acetate wound size data
Time Excluded Acetate Excluded Photograph Included Acetate Included Photograph
Day 1 2.31 0.78 0.90 0.39n 3.38 1.82 2.85 1.57w
Week 1 0.91 0.74 0.65 0.54w 2.28 1.78 2.17 1.65
Week 2 0.78 1.03 0.62 0.55 1.96 1.70 1.96 1.64
All data cm2.
np < 0.001 vs. acetate,
wp < 0.05 vs. acetate, paired t test. MeanS.D.
Table 1. Demographic characteristics and patient disposition
Variable GAM501 Combined (N572) FCG Combined (N533) Standard of Care (N519)
Age (years) Mean (SD) 57.9 (10.9) 56.2 (12.0) 54.8 (12.3)
Median (range) 60 (31–77) 59 (30–83) 51 (38–86)
Gender [n (%)]
Male 50 (69%) 25 (76%) 15 (79%)
Female 22 (31%) 8 (24%) 4 (21%)
Caucasian 46 (64%) 21 (64%) 12 (63%)
Black or African American 10 (14%) 4 (12%) 2 (11%)
Hispanic 16 (22%) 8 (24%) 4 (21%)
American Indian or Alaskan Native 0 (0%) 0 (0%) 1 (5%)
Baseline ulcer size meanSD,cm2 3.1 1.7 2.9 1.1 2.8 1.3
Ulcer duration meanSD, Months 18.4 28.6 17.1 26.8 11.6 12.0
Type 1 diabetes (% in group) 6 (8%) 2 (6%) 2 (11%)
Type 2 diabetes 63 (88%) 29 (88%) 16 (84%)
Unspecified type of diabetes 3 (4%) 2 (6%) 1 (5%)
Diabetes duration (mean, years) 15 14 13
Hb A1c % (SD) 8.06 (1.82) 8.07 (1.45) 7.85 (1.34)
BMI, mean (SD) 33.70 (7.54) 33.08 (7.13) 34.15 (7.18)
BMI, median (range) 32.2 (22.2–66.6) 32.3 (20.7–50.2) 34.2 (23.7–49.4)
Completed the study 67 (92%) 31 (84%) 18 (95%)
Withdrew from the study 5 (7%) 2 (5%) 1 (5)
Adverse event 0 (0%) 2 (5%) 0 (0%)
Patient noncompliance 0 (0%) 0 (0%) 1 (5%)
Lost to follow-up 5 (7%) 0 (0%) 0 (0%)
No significant differences between groups for any parameter.
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for testing interventions as they tend to heal with SOC.5
Indeed our data showed a 49% complete closure incidence
in the patients who had wound sizes < 1.35 cm2 or closure
rates > 33% during Run-in by photographic analysis.
Since the entry criteria included a requirement for chronic
non-closure it may seem surprising that some patients were
excluded during Run-in (five by acetate and 35 by photo-
graphic data). This may have been due to better SOC
treatment and use of an off-loading boot during the Run-
in period.
In the primary SAP1 analysis the wound closure inci-
dence in SOC of 31% is slightly greater than the published
12 week incidence of  25%.5 The supportive care of
weekly visits and encouraged compliance to off-loading
may have had a positive effect. The numerically greater
complete closure incidence over SOC observed in the
GAM501 and FCG groups was not statistically signifi-
cant; whether the lack of significance was due to small
sample size could be determined by future studies. Despite
the small group sizes, the fact that both GAM501 and
FCG generated similar improvements in wound healing
rates and complete closure incidence was surprising based
on preclinical studies which suggested that FCG alone
would not substantially increase the incidence of healing
or complete wound closure, and thus serve as an addi-
tional control group. One possible explanation is that the
patients had more bleeding at the time of treatment due to
debridement than in the preclinical models, where repeat
debridement was not performed before treatment. One
limitation of our study is that we did not measure PDGF
expression or duration in the patient’s wounds. However,
in preclinical studies PDGF expression in response to
GAM501 persisted for about 1 week.10,11 Collagen (as
used in both GAM501 and FCG) is known to activate
platelets and release PDGF.17 We confirmed in vitro that
exposure of human platelets to FCG triggers PDGF re-
lease. Thus the FCG group might also have augmented
PDGF at the wound site to promote a wound healing re-
sponse; defining the mechanisms of action of FCG is wor-
thy of further study.
The results obtained from analysis of photographs dur-
ing Run-in were quite disparate from the acetate tracings.
The finding that 35 of 113 (31%) patients were excluded
when the primary data was photographs is noteworthy.
Acetate tracings have traditionally been used for wound
measurements, as they are easy to perform and can con-
form to curved foot surfaces. Their disadvantages include
blood in and around the wound or spreading on the ace-
tate obscuring the wound edge, slippage of the acetate
during tracing, and differing tracing techniques. In the
current study, investigators and study coordinators were
trained extensively and very detailed procedures were to be
followed. Despite this effort, findings from the post hoc
comparison of acetate- and photograph-based measure-
ments revealed significant discrepancies and provide im-
portant lessons for future trials. Planimetry of acetate
tracings gave systematically larger areas than planimetry
of photographs (Table 2). The comparison also suggests a
systematic overestimation on Day 1 which seemed to be
clustered at a few sites. There are several possible explana-
tions. The investigators at these sites may have been more
aggressive in wound debridement causing more wound
bleeding to spread on the acetate and thereby making the
wound appear larger. It is also possible that enthusiasm
Table 3. Cumulative wound healing rates, decrease in radius in mm/week
Time period SOC FCG GAM501
Run-in (Day14–Day 1) 0.06 0.32 0.08 0.61 0.02 0.58
Day 1–Week 1 0.78 1.53 1.97 1.77n ,z 1.46 1.37z
Day 1–Week 2 0.63 0.71w 1.37 0.93n ,z 1.06 0.92z
Day 1–Week 3 0.63 0.57w 1.00 0.66z 0.83 0.73z
Day 1–Week 4 0.52 0.58w 0.80 0.52z 0.73 0.58z
Positive number indicates radius decrease. Between Groups Test:
np < 0.05 compared with SOC by one way ANOVA; Within Group Tests: compared with Run-in:
wp < 0.05.
zp < 0.002. MeanSD.
Table 4. Weekly wound healing rates; decrease in radius in mm/week from run-in through week 4, SAP2
Time period SOC FCG GAM501
Run in 0.06 0.32 0.08 0.61 0.02 0.58
Day1–Week1 0.78 1.53 1.97 1.77n ,w 1.46 1.37n ,w
Week1–Week2 0.48 0.90 0.81 0.85n ,w 0.63 1.05n ,w
Week2–Week3 0.68 1.16z 0.29 0.83 0.44 0.89n ,w
Week3–Week4 0.01 0.94 0.34 1.14 0.72 1.29n ,w
np < 0.001 from 0.0 rate of change, t test.
wp < 0.01 from Run-in.
zp < 0.05 from Run-in, t-test. MeanSD.
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for enrolling patients for a possibly beneficial treatment
led to unconscious bias at the critical entry determination.
One of the important lessons from our trial is that a more
highly standardized and accurate method of sizing wounds
is needed. While photographs lack the ability to eliminate
curvature as a variable, they do lead to more objective and
verifiable data. If acetate tracings are to be used as primary
data, a quality control mechanism, likely using photo-
graphs, should be employed during trial execution.
Recently available photographic equipment with laser
scanning to correct for wound surface curvature may pro-
vide more accurate and reproducible data.
When we analyzed the patient data in SAP2, we again
found a trend for improved complete closure of wounds
for GAM501 and FCG compared with SOC, however,
with only 82 patients the statistical power may have been
insufficient. In contrast to the insignificant rates of change
of wound radius using acetate data, which was likely bi-
ased by the apparent large errors over-estimating wound
size measurements on Day 1, with photographic data there
were significant differences. Pair-wise comparison between
groups showed that FCG was significantly better than
SOC for the time periods of Day1–Week1 and Day1–
Week2 (Table 3). Within each group there was an imme-
diate large and highly significant increase in cumulative
wound-healing rate from Run-in to Week-1 that remained
significant but decreased numerically at all subsequent
time periods for both GAM501 and FCG. In contrast,
the SOC group did not show a statistical increase in
cumulative healing rate until Week 2, and it remained
fairly constant. This comparison suggests a time-depen-
dent effect of both GAM501 and FCG on wound-healing
rate that appears to be different than SOC. Further insight
is gained from the individual weekly wound healing rates.
Compared with Run-in, the weekly healing rate only
changed significantly in the SOC group at Week 2–3; the
only interventions being weekly visits and encouraging the
use of off-loading. In contrast, for both the GAM501 and
FCG groups the healing rate increased markedly during
Week 1 and then declined slowly over the next 3 weeks
(Table 4). Thus, both GAM501 and FCG appeared to
cause a large and rapid time-dependent effect on tissue
growth rates. The study as completed was underpowered
to detect any difference between the two interventions,
which will be an important question for future trials. The
study protocol limited treatment with GAM501 and FCG
to one or two treatments. Based on the safety data and the
timing of significant improvement in healing rates ob-
served in this study, multiple treatments hold promise to
further increase overall complete wound closure in future
adequately powered trials.
We conclude from this exploratory trial that a single
application of GAM501 or FCG increases the healing rate
of neuropathic DFUs for the first two weeks after treat-
ment; whereas SOC with weekly visits seems to have a
much smaller and delayed effect on wound healing rate.
This suggests that more frequent applications of GAM501
or FCG hold promise to significantly improve overall
incidence of complete wound closure. Whether one or
more administrations of GAM501 has advantages over
FCG alone in certain circumstances, such as larger or
more difficult to treat wounds, will require testing in future
trials.
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